Defects in spermatogenesis of men with Y chromosome microdeletions by Racoviță, Stela
The 8th International Medical Congress for Students and Young Doctors 
 ____________________________________________________________________________________ 
289 
 
318. GENETIC MECHANISMS OF DRUG RESISTANCE IN CANCER 
CHEMOTHERAPY  
Author: Ana Margineanu  
Scientific adviser: Peciuleac Ludmila, PhD, Associate professor, Department of Molecular 
biology and Human genetics, Nicolae Testemitanu State University of Medicine and Pharmacy 
of the Republic of Moldova.  
 
Introduction. One of the major problems in cancer chemotherapy is the development of drug 
resistance during treatment. Currently, 90% of failures in chemotherapy are during the invasion 
and metastasis of cancers related to drug resistance that can develop in different mechanisms.  
Aim of the study. To study genetic mechanisms of drug resistance in cancer chemotherapy.  
Materials and methods.: This paper is a descriptive research, based on retrospective analysis. 
Analysis of statistical data, current management documents, reports, studies, bibliographic and 
digital sources have been carried out with reference to the topic.  
Results. The study of the genetic mechanisms of drug resistance in the treatment of cancer has 
identified the presence of different extracellular and intracellular mechanisms: tumor 
heterogeneity, tumor microenvironment, cancer stem cells, inhibition of cell death, inactivation 
of anticancer drugs, multi-drug resistance (MDR), changing drug metabolism, changing 
chemotherapeutic agents targets, enhancing DNA repair, gene amplification, epigenetic 
changes, microRNA. Responsible for multiplication, growth and metastasis have been shown 
to be some genes that encode for kinases. According to the latest studies, use of kinase inhibitor 
preparations is effective in both stopping progression of cancer and increasing the intracellular 
concentration of the preparation in MDR cells.  
Conclusions. Cancer drug resistance is a complex phenomenon determined by numerous 
mechanisms and some genes. Gaining knowledge about these particularities and performing 
genetic tests make it possible to avoid the misuse of the preparations, in order to prevent the 
chemotoxicity on the organism and affect the systems with a high division rate.  
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Introduction. Male infertility has multiple etiology, most commonly caused by 
spermatogenesis disorders, clinically manifested by oligo/azoospermia. Until recently, Y 
microdeletion had little clinical significance since men with a deletion were considered unable 
to reproduce. However, by utilizing of Intracytoplasmic sperm injection (ICSI) and Testicular 
sperm extraction (TESE) it is now possible for oligo/azoospermic men with Y microdeletion 
to father children.  
Aim of the study. To analyze the type of defect in spermatogenesis associated with specific Y 
deletions found in our IVF program, for prevention the transmission of these deletions through 
ICSI to offspring.  
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Materials and methods. A group of 46 infertile men were investigated during genetic 
counseling among infertile couples referred for ART treatment. Criteria for including patients 
were fulfilled if they presented with oligo/azoospermia, raised or normal levels of FSH, LH 
and testosterone. Genomic DNA was isolated and used to analyze AZF microdeletions by PCR. 
The regions and sequence-tagged sites of AZFa (SY86, SY84), AZFb (SY127, SY134), and 
AZFc (SY254, SY255) were sequenced by multiplex PCR. Five non-obstructive azoospermic 
men had Y chromosomal microdeletions. All five Y-microdeleted men underwent 
microsurgical observation of testicular architecture and quantitative histology of 
spermatogenesis in a strip of testicular tissue. The results were compared with the different 
type of Y microdeletion.  
Results. Deletions of Y chromosome were seen in the AZFc regions of 2 patients, deleted 
markers were sY254 and sY255. In both men with AZFc deletions, the histological defects 
were variable, but no sperm were found. In only one case the defect of Sertoli cell-only 
syndrome (SCOS) in patient with microdeletions in each region of AZFa-sY84, sY86; AZFb-
sY127, sY134; AZFc-sY254, sY255 was present. One patient with deletion of AZFb (SY127, 
SY134) had spermatogenetic maturation arrest. In all men with AZF microdeletions of the Y 
chromosome, we found severe spermatogenic defects: however, we also did not find, in all of 
them, mature sperm sufficient for ICSI. The patients were advised to use sperm from the donor 
for ICSI and IVF.  
Conclusions. This study highlights for all couples with the diagnosis of male infertility with 
oligo/azoospermia the need of genetic testing and counseling prior to employment of assisted 
reproduction techniques. This is important for providing a firm diagnosis and fertility treatment 
to couples with infertility and for prevention of the transmission of AZFc deletions through 
ICSI to offspring.  
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Introduction. Von Willebrand disease (VWD), the most common inherited bleeding disorder 
in humans, is a heterogeneous disorder caused by a partial quantitative (type 1 VWD), 
qualitative (type 2 VWD) or severe quantitative (type 3 VWD) deficiency of von Willebrand 
factor protein (VWF). It is characterised clinically by mucocutaneous bleeding, such as 
epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma. VWF is a large, 
multimeric protein that plays a role in platelet adhesion and serves as a carrier for the 
thrombotic protein factor VIII. The VWF gene is located at the short arm of chromosome 12 
(12p13.31). Depending on its type, VWD can either have an autosomal dominant inheritance 
pattern (type 1, type 2A, 2B, 2M) or an autosomal recessive inheritance pattern (type 2N and 
type 3).  
Aim of the study. Expanding the understanding of the genetic basis of different types of VWD.  
Materials and methods. This study is based on a review of different articles from the open 
access data bases: PubMed, OMIM, SpringerLink.  
